BACKGROUND: Decline in upper-body function and development of upper-body symptoms are adverse effects of breast cancer therapy and may affect functional independence, particularly among older survivors. The long-term risks and predictors are poorly understood. OBJECTIVE: To characterize the risk of decline in upper-body function and development of symptoms over 4 years of follow-up. DESIGN: We used a prospective cohort design. PARTICIPANTS: Six hundred and forty-four early stage breast cancer patients 65 years old or older at surgery enrolled in Rhode Island, North Carolina, Minnesota, and Los Angeles between 1996 and 1999. MEASUREMENTS: Upper-body function and symptoms were self-reported at baseline, 6, 15 months, and annually thereafter to 51 months after surgery. RESULTS: One half of the participants had a decline in upper-body function and one-quarter developed upper-body symptoms. Breast cancer patients were 5-fold more likely to have a decline in upper-body function over 4 years of follow-up than a similar cohort without breast cancer. Better baseline mental health protected against a decline in upper-body function (odds ratio [OR]=0.93, 95% confidence interval [CI] 0.88 to 0.97 for 8-point higher mental health index). Baseline obesity (OR for body mass index [BMI] > or =30 kg/m2 vs <30 kg/m2=2.5, CI=1.6 to 4.0) and axillary node dissection (OR for axillary dissection vs not=3.9, CI=1.1 to 14) predicted the development of upper-body symptoms. CONCLUSIONS: Primary care physicians should address upper-body function and symptoms with older breast cancer patients, and inform them that these complications of breast cancer treatment are common.
BACKGROUND: Decline in upper-body function and development of upper-body symptoms are adverse effects of breast cancer therapy and may affect functional independence, particularly among older survivors. The long-term risks and predictors are poorly understood. OBJECTIVE: To characterize the risk of decline in upper-body function and development of symptoms over 4 years of follow-up. DESIGN: We used a prospective cohort design. PARTICIPANTS: Six hundred and forty-four early stage breast cancerpatients 65 years old or older at surgery enrolled in Rhode Island, North Carolina, Minnesota, and Los Angeles between 1996 and 1999. MEASUREMENTS: Upper-body function and symptoms were self-reported at baseline, 6, 15 months, and annually thereafter to 51 months after surgery. RESULTS: One half of the participants had a decline in upper-body function and one-quarter developed upper-body symptoms. Breast cancerpatients were 5-fold more likely to have a decline in upper-body function over 4 years of follow-up than a similar cohort without breast cancer. Better baseline mental health protected against a decline in upper-body function (odds ratio [OR]=0.93, 95% confidence interval [CI] 0.88 to 0.97 for 8-point higher mental health index). Baseline obesity (OR for body mass index [BMI] > or =30 kg/m2 vs <30 kg/m2=2.5, CI=1.6 to 4.0) and axillary node dissection (OR for axillary dissection vs not=3.9, CI=1.1 to 14) predicted the development of upper-body symptoms. CONCLUSIONS: Primary care physicians should address upper-body function and symptoms with older breast cancerpatients, and inform them that these complications of breast cancer treatment are common.
Authors: Jeanne S Mandelblatt; Stephen B Edge; Neal J Meropol; Ruby Senie; Theodore Tsangaris; Luther Grey; Burt Peterson; Yi-Ting Hwang; Jane C Weeks Journal: Cancer Date: 2002-12-15 Impact factor: 6.860
Authors: Karen P L Yap; David R McCready; Steven Narod; Lee A Manchul; Maureen Trudeau; Anthony Fyles Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: Winkle Kwan; Jeremy Jackson; Lorna M Weir; Carol Dingee; Greg McGregor; Ivo A Olivotto Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: M P Schijven; A J J M Vingerhoets; H J T Rutten; G A P Nieuwenhuijzen; R M H Roumen; M E van Bussel; A C Voogd Journal: Eur J Surg Oncol Date: 2003-05 Impact factor: 4.424
Authors: Larissa K F Temple; Roberta Baron; Hiram S Cody; Jane V Fey; Howard T Thaler; Patrick I Borgen; Alexander S Heerdt; Leslie L Montgomery; Jeanne A Petrek; Kimberly J Van Zee Journal: Ann Surg Oncol Date: 2002-08 Impact factor: 5.344
Authors: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid L Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Johan S Rietman; Pieter U Dijkstra; Jan H B Geertzen; Peter Baas; Jaap De Vries; Wil Dolsma; Johan W Groothoff; Willem H Eisma; Harald J Hoekstra Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Joan M Neuner; Nathan Zokoe; Emily L McGinley; Liliana E Pezzin; Tina W F Yen; Marilyn M Schapira; Ann B Nattinger Journal: Breast Date: 2014-07-14 Impact factor: 4.380
Authors: Jacek A Kopec; Linda H Colangelo; Stephanie R Land; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Takamaru Ashikaga; Joseph P Costatino; Norman Wolmark; Patricia A Ganz Journal: J Support Oncol Date: 2013-03
Authors: Sharon L Kilbreath; Kathryn M Refshauge; Jane M Beith; Leigh C Ward; Judy M Simpson; Ross D Hansen Journal: BMC Cancer Date: 2006-12-01 Impact factor: 4.430
Authors: Iwona Głowacka-Mrotek; Magdalena Sowa; Zygmunt Siedlecki; Tomasz Nowikiewicz; Wojciech Hagner; Wojciech Zegarski Journal: Breast Cancer Res Treat Date: 2017-03-07 Impact factor: 4.872